Literature DB >> 24781934

[Importance of Quick, partial thromboplastin time, and Co].

G Siegert1.   

Abstract

The Quick test and activated partial thromboplastin time (aPTT) are so-called global assays used to characterize different steps in plasmatic hemostasis. They reflect hemostasis in its classical differentiation into extrinsic and intrinsic pathways. However, they do not cover physiological aspects of cell-based hemostasis. Results are not necessarily congruent with a specific clinical situation and do not replace a complete medical history. Patients suffering from hemophilia A or B, for example, have normal Quick test results. Severe factor XII deficiency reveals an extreme aPTT prolongation without a significant bleeding tendency. In Lupus patients, aPTT is also prolonged with clinically a rather increased thrombotic risk. Fibrinogen as a substrate of coagulation discloses pathological results in both global tests in case of considerable reduction. In case of positive bleeding history and a normal global assay, disorders in platelets, von Willebrand factor and factor XIII must be considered. Reduced Quick test results may be expected in factor VII, II, V, or X deficiency. Disorders of liver synthesis of coagulation factors as well as vitamin K deficiency will be indicated by the Quick test rather than by aPTT. The most frequent hereditary reasons for a prolonged aPTT are hemophilia A and B as well as von Willebrand disease. In case of an acquired bleeding tendency, the diagnostic strategy must include autoantibodies. The sensitivity of the aPTT reagent varies widely. Low-molecular weight heparin and pentasaccharides do not influence the test. Oral direct inhibitors may reveal pathological results in a reagent-dependent manner.

Entities:  

Mesh:

Year:  2014        PMID: 24781934     DOI: 10.1007/s00108-013-3420-7

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  3 in total

1.  Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis.

Authors:  V Pengo; A Tripodi; G Reber; J H Rand; T L Ortel; M Galli; P G De Groot
Journal:  J Thromb Haemost       Date:  2009-07-17       Impact factor: 5.824

2.  Main considerable factors for correct laboratory test interpretation under DOA treatment.

Authors:  Helen Mani; Edelgard Lindhoff-Last
Journal:  Thromb J       Date:  2013-11-01

Review 3.  Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease.

Authors:  Raffaele De Caterina; Steen Husted; Lars Wallentin; Felicita Andreotti; Harald Arnesen; Fedor Bachmann; Colin Baigent; Kurt Huber; Jørgen Jespersen; Steen Dalby Kristensen; Gregory Y H Lip; João Morais; Lars Hvilsted Rasmussen; Agneta Siegbahn; Freek W A Verheugt; Jeffrey I Weitz
Journal:  Thromb Haemost       Date:  2013-11-14       Impact factor: 5.249

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.